Expression of matrix metalloproteinase-10 in non-metastatic prostate cancer: Correlation with an imbalance in cell proliferation and apoptosis.

Detecting malignant melanoma at an early stage, monitoring therapy, predicting recurrence and identifying patients at risk for metastasis continue to be a challenging and demanding objective The last two decades have witnessed innovations in the field of melanoma biomarkers However, global agreement concerning monitoring and early detection has yet to be reached This is a review of the current literature regarding melanoma biomarkers including demographic, clinical, pathological and molecular biomarkers that are produced by melanoma or non-melanoma cells A number of these biomarkers demonstrate promising results as possible methods for early detection, predicting recurrence and monitoring therapy Other biomarkers appear to be promising for identifying patients at risk for metastasis We reviewed the most pertinent information in the field thus far and how this knowledge can impact, or not, the management of melanoma patients prognostically and therapeutically